<?xml version="1.0" encoding="UTF-8"?>
<p>There are several clinical trials that are ongoing that have very different eligibility criteria from the severely affected to post exposure individuals.
 <xref rid="jca21806-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> The patient selection may vary between countries. The FDA allowed the use of CP to patients who met the following criteria
 <xref rid="jca21806-bib-0016" ref-type="ref">
  <sup>16</sup>
 </xref>:
 <list list-type="bullet" id="jca21806-list-0002">
  <list-item id="jca21806-li-0006">
   <p>Laboratory confirmed COVID‐19</p>
  </list-item>
  <list-item id="jca21806-li-0007">
   <p>Severe or immediately life‐threatening COVID‐19.</p>
   <list list-type="bullet" id="jca21806-list-0003">
    <list-item id="jca21806-li-0008">
     <p>Severe disease is defined as one or more of the following:</p>
     <list list-type="bullet" id="jca21806-list-0004">
      <list-item id="jca21806-li-0009">
       <p>Dyspnea,</p>
      </list-item>
      <list-item id="jca21806-li-0010">
       <p>Tachypnea ≥ 30/min,</p>
      </list-item>
      <list-item id="jca21806-li-0011">
       <p>blood oxygen saturation ≤ 93%,</p>
      </list-item>
      <list-item id="jca21806-li-0012">
       <p>PaO
        <sub>2</sub>/FiO
        <sub>2</sub> &lt; 300,
       </p>
      </list-item>
      <list-item id="jca21806-li-0013">
       <p>lung infiltrates &gt;50% within 24‐48 hours</p>
      </list-item>
     </list>
    </list-item>
    <list-item id="jca21806-li-0014">
     <p>The life‐threatening disease is defined as one or more of the following:</p>
     <list list-type="bullet" id="jca21806-list-0005">
      <list-item id="jca21806-li-0015">
       <p>respiratory failure,</p>
      </list-item>
      <list-item id="jca21806-li-0016">
       <p>septic shock,</p>
      </list-item>
      <list-item id="jca21806-li-0017">
       <p>multiple organ dysfunction</p>
      </list-item>
     </list>
    </list-item>
   </list>
  </list-item>
 </list>
</p>
